BIOMAT Database Logo BIOMAT Database Logo

Dapsone versus topical immunotherapy in alopecia areata. 1995

H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Department of Dermatology, University Hospital Nijmegen, The Netherlands.

Twenty-seven patients with severe alopecia areata were treated with dapsone. The results of a mean treatment duration of 10 +/- 0.5 months are reported, and compared with the results of long-term topical immunotherapy obtained previously at the same institute. The efficacy of dapsone proved to be markedly inferior to that of topical immunotherapy. The percentage of patients showing regrowth of hair during treatment with dapsone was comparable with the occurrence of spontaneous regrowth of hair reported in the literature.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003622 Dapsone A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Diaminodiphenylsulfone,Sulfonyldianiline,4,4'-Diaminophenyl Sulfone,Avlosulfone,DADPS,Dapsoderm-X,Dapson-Fatol,Diaphenylsulfone,Disulone,Sulfona,4,4' Diaminophenyl Sulfone,Sulfone, 4,4'-Diaminophenyl
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000506 Alopecia Areata Loss of scalp and body hair involving microscopically inflammatory patchy areas. Alopecia Circumscripta

Related Publications

H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy in alopecia areata.
January 2010, International journal of trichology,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy in alopecia areata.
May 1991, The Journal of investigative dermatology,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
[Alopecia areata; pathogenesis and topical immunotherapy].
June 1989, Nederlands tijdschrift voor geneeskunde,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Alopecia areata. Pathogenesis and topical immunotherapy.
March 1990, International journal of dermatology,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy in children with alopecia areata.
May 1995, The Journal of investigative dermatology,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Alopecia areata: topical immunotherapy treatment with diphencyprone.
March 2008, Journal of the European Academy of Dermatology and Venereology : JEADV,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Alopecia areata: topical immunotherapy--application and practical problems.
November 1999, Journal of cutaneous medicine and surgery,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy with diphencyprone in Indians with alopecia areata.
November 1998, Clinical and experimental dermatology,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy in alopecia areata. What, how, and why?
October 1996, Dermatologic clinics,
H M van Baar, and C J van der Vleuten, and P C van de Kerkhof
Topical immunotherapy of alopecia areata. A follow-up study.
January 1986, Acta dermato-venereologica,
Copied contents to your clipboard!